Tesaro Inc. (TSRO) Trading Down 1.4%
Tesaro Inc. (NASDAQ:TSRO) fell 1.4% on Monday . The stock traded as low as $84.25 and last traded at $85.22, with a volume of 356,174 shares traded. The stock had previously closed at $86.46.
Several brokerages have weighed in on TSRO. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Tesaro in a research report on Saturday, May 14th. Jefferies Group reaffirmed a “buy” rating on shares of Tesaro in a research report on Sunday, May 8th. Leerink Swann reaffirmed a “buy” rating on shares of Tesaro in a research report on Monday, June 6th. FBR & Co reaffirmed a “buy” rating and issued a $65.00 target price on shares of Tesaro in a research report on Friday, May 6th. Finally, Zacks Investment Research raised Tesaro from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $86.43.
The stock’s market capitalization is $4.41 billion. The firm’s 50-day moving average is $91.74 and its 200 day moving average is $57.18.
Tesaro (NASDAQ:TSRO) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.71) by $0.43. The business had revenue of $36.60 million for the quarter, compared to analysts’ expectations of $4.98 million. During the same quarter in the previous year, the company earned ($1.51) earnings per share. Equities analysts forecast that Tesaro Inc. will post ($7.31) EPS for the current fiscal year.
In other news, VP Edward C. English sold 7,000 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $40.75, for a total transaction of $285,250.00. Following the completion of the transaction, the vice president now directly owns 3,500 shares of the company’s stock, valued at $142,625. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Jeffrey H. Hanke sold 12,500 shares of the company’s stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $74.35, for a total transaction of $929,375.00. Following the transaction, the vice president now directly owns 12,500 shares of the company’s stock, valued at $929,375. The disclosure for this sale can be found here.
An institutional investor recently raised its position in Tesaro stock. Bank of Montreal Can boosted its stake in shares of Tesaro Inc. (NASDAQ:TSRO) by 9,925.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,362 shares of the biopharmaceutical company’s stock after buying an additional 24,119 shares during the period. Bank of Montreal Can owned approximately 0.06% of Tesaro worth $1,275,000 at the end of the most recent reporting period.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.